Academic Department of Surgery, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Anaesthesia. 2024 Sep;79(9):945-956. doi: 10.1111/anae.16324. Epub 2024 May 27.
Multimorbidity poses a global challenge to healthcare delivery. This study aimed to describe the prevalence of multimorbidity, common disease combinations and outcomes in a contemporary cohort of patients undergoing major abdominal surgery.
This was a pre-planned analysis of a prospective, multicentre, international study investigating cardiovascular complications after major abdominal surgery conducted in 446 hospitals in 29 countries across Europe. The primary outcome was 30-day postoperative mortality. The secondary outcome measure was the incidence of complications within 30 days of surgery.
Of 24,227 patients, 7006 (28.9%) had one long-term condition and 10,486 (43.9%) had multimorbidity (two or more long-term health conditions). The most common conditions were primary cancer (39.6%); hypertension (37.9%); chronic kidney disease (17.4%); and diabetes (15.4%). Patients with multimorbidity had a higher incidence of frailty compared with patients ≤ 1 long-term health condition. Mortality was higher in patients with one long-term health condition (adjusted odds ratio 1.93 (95%CI 1.16-3.23)) and multimorbidity (adjusted odds ratio 2.22 (95%CI 1.35-3.64)). Frailty and ASA physical status 3-5 mediated an estimated 31.7% of the 30-day mortality in patients with one long-term health condition (adjusted odds ratio 1.30 (95%CI 1.12-1.51)) and an estimated 36.9% of the 30-day mortality in patients with multimorbidity (adjusted odds ratio 1.61 (95%CI 1.36-1.91)). There was no improvement in 30-day mortality in patients with multimorbidity who received pre-operative medical assessment.
Multimorbidity is common and outcomes are poor among surgical patients across Europe. Addressing multimorbidity in elective and emergency patients requires innovative strategies to account for frailty and disease control. The development of such strategies, that integrate care targeting whole surgical pathways to strengthen current systems, is urgently needed for multimorbid patients. Interventional trials are warranted to determine the effectiveness of targeted management for surgical patients with multimorbidity.
多种疾病给医疗保健带来了全球性挑战。本研究旨在描述接受大型腹部手术的当代患者中多种疾病的患病率、常见疾病组合和结局。
这是一项针对欧洲 29 个国家 446 家医院进行的大型腹部手术后心血管并发症的前瞻性、多中心、国际研究的预先计划分析。主要结局是术后 30 天的死亡率。次要结局指标是手术 30 天内并发症的发生率。
在 24227 名患者中,7006 名(28.9%)有 1 种长期疾病,10486 名(43.9%)有多发性疾病(2 种或以上长期健康状况)。最常见的疾病是原发性癌症(39.6%);高血压(37.9%);慢性肾脏病(17.4%);和糖尿病(15.4%)。患有多种疾病的患者与患有≤1 种长期健康状况的患者相比,虚弱的发生率更高。有 1 种长期健康状况的患者死亡率更高(调整后的优势比 1.93(95%可信区间 1.16-3.23))和多发性疾病(调整后的优势比 2.22(95%可信区间 1.35-3.64))。虚弱和美国麻醉医师协会身体状况 3-5 估计在患有 1 种长期健康状况的患者中,30 天死亡率的 31.7%(调整后的优势比 1.30(95%可信区间 1.12-1.51))和患有多种疾病的患者中 30 天死亡率的 36.9%(调整后的优势比 1.61(95%可信区间 1.36-1.91))。在接受术前评估的患有多种疾病的患者中,30 天死亡率并没有改善。
在欧洲的外科患者中,多种疾病很常见,且预后不佳。需要创新策略来解决择期和急诊患者的多种疾病问题,以应对虚弱和疾病控制。迫切需要为多种疾病患者制定整合针对整个外科通路的护理策略来加强现有系统。需要进行干预性试验来确定针对多种疾病的外科患者进行靶向管理的有效性。